These are the 5 largest stocks in Rakesh Jhunjhunwala’s portfolio, holding values ​​ranging from ₹1,000 cr to ₹11,000 cr

Titan, backed by the Tata Group, is at the top of its portfolio pyramid. While Star Health, Metro Brands and Tata Motors are among its recent investments. He has remained at Titan and Crisil since 2015. These five stocks represent almost 77% of the wealth in his portfolio.

According to data from Trendlyne, the big bull’s wealth soared 25% in less than two weeks of August for ₹31,833.77 crores. His wealth was about ₹25,425.88 crores in June and at a record high ₹33,753.92 crores in March this year.

Of this total, its stake is valued at approximately ₹11,086.9 crore from Titan, ₹7,017.5 crore in Star Health, ₹3,348.8 crore in Metro brands, ₹1,731.1 crore in Tata Motors, and ₹1,301.9 crore in Crisil as of August 12, 2022.

Since August 13, 2015, Titan shares have emerged as a mutli-bagger with a jaw-dropping gain of around 655% to date. Crisil, however, has soared nearly 71% so far in those years.

Star Health and Metro Brands listed in December last year. General health insurer has fallen more than 23% since its listing date, but has been on a recovery path since July 2022. Meanwhile, footwear company Metro Brands is up more than 76% since its listing date. market debut. He invested in Tata Motors during the September 2020 quarter, and since then the shares have soared 217.5%, according to available BSE data.

Here are the details of Jhunjhunwala’s shareholding in these shares:

– As of June 30, 2022, the market tycoon owns 44,850,970 shares or 5.1% of Titan.

– He owns 100,753,935 shares or 17.5% of Star Health as of June 30, 2022.

– Its shareholding amounts to 39,153,600 shares or 14.4% at the end of the June quarter 2022.

– While owning 36,250,000 shares or 1.1% of Tata Motors at the end of June 2022 quarter.

– Jhunjhunwala’s stake in Crisil is approximately 4,000,000 shares or 1.1% as of June 30, 2022.

Here is an overview of the actions on BSE currently. Analysts gave an optimistic view of some of these stocks going forward:

Titan Company:

On BSE, Titan stocks are around ₹2,471.95 each as of August 12. The market capitalization of the company is ₹2 19,456.30 crore.

Shares have soared at least 35.55% on Dalal Street in a year. Stocks were around ₹1,823.55 on August 12 last year.

JM Financial analysts Richard Liu, Mehul Desai and Sumanyu Saraf said in their report, “Titan is off to a strong post-pandemic start with strong measures across all key businesses. Sales momentum has revived strongly in jewelry after a weak Mar-T, with “normalized” growth of 23% (3-year CAGR), which is one of the best seen in the consumer categories we follow. Much of the executive conversations revolved around recruiting new consumers into the ecosystem to build a “funnel for the future”. The growth, better mix and resulting cost leverage has resulted in even better profitability than we had expected.”

They also said: “Given the strength of all segments, management again underlined its bullish overall outlook with a forecast for jewelry growth of 2.5x five-year, or a CAGR of 20% in FY22. -27E with a near-term margin expected in the 12-13% range.Watches also appears to have established a higher base now, with Wearables emerging as a major new driver.The same is true for Eyewear, where recent restructuring has delivered strong results. We expect the stock to remain strong based on this result, but an NTM > 60x PER strikes us as an overly rich entry point.”

JM Financial analysts have set a 12-month price target of ₹2,620 on Titan.

Star Health and allied insurances:

On BSE, Star Health shares are at ₹696.10 each as of August 12. The market capitalization of the company is approximately ₹40,104.98 crores.

Star Health made its market debut on December 10 last year. The company launched its IPO from November 30 to December 3 last year at a price range of ₹870 to ₹900 each. The IPO saw sluggish demand as it did not fully subscribe.

The shares are up more than 42% since July this year.

HDFC Securities analysts Sahej Mittal, Krishnan ASV, Deepak Shinde and Neelam Bhatia in their research note said: “Capitalizing on a first mover advantage and significant regulatory arbitrage, STARHEAL is positioning itself as the largest stand-alone health insurer (FY22: 33% of market-share), anchored on an extremely solid and highly productive distribution network dominated by agencies and a business mix dominated by retail (FY22: ~90% of GDPI). Despite potential regulatory convergence, we believe STARHEAL has significant leeway to evolve into a high-quality franchise, which translates into higher earnings quality.”

Further, the analysts said, “Having passed the agency channel, we argue that the company now needs to build a credible banca strategy in order to maintain its long-term lead. We expect STARHEAL to generate revenue/CAGR APAT of 32% / 38% in FY20-FY24E and healthy ROEs in the range of 10% / 16% in FY23E/24E We start with a BUY and a DCF-derived target price of INR 860 (53x FY24E AEPS and 10x FY24E P/ ABV).”

Metro brands:

On the BSE, the company’s shares are approximately ₹854.30 each. Shares had hit a new 52-week high of ₹869 each Friday. The market capitalization of the company is approximately ₹23,199.04 crores.

Metro Brands shares went public last year on Dec. 21. The IPO had a price range of ₹485 to ₹500 per piece. 100% book building subscribed 3.64 times on the primary market.

Since its IPO, Metro Brands shares have soared more than 76% on BSE. So far in 2022, shares are up more than 91.5%, which has made many investors rich, including Jhunjhunwala.

Akhil Parekh Research Analyst and Kevin Shah Research Associate at Centrum said in their report, “Entry into new geographies, tie-up with international brands (Crocs and Fitflops) coupled with a variable cost structure should help the business grow sales/EBITDA/PAT CAGR to 34/36/47% respectively on FY22-24E On a low basis, we expect volume (number of pairs) to grow at a CAGR of 25% and an ASP of 7% on FY22-24E. We have increased our EPS estimates by 49/36% each for FY23/FY24. We maintain our rating at ADD with a target price of Rs821. We continue to value the stock at 48x FY24E.”

Tata engines:

On BSE, Tata Motors shares are around ₹477.50 each. The company has a market capitalization of approximately ₹1,58,586.12 crore.

Shares of Tata Motors have soared more than 56% in one year. Stocks were around ₹306 on August 12.

JM Financial analysts Vivek Kumar and Ronak Mehta in their research note said, “TTMT expects the chip shortage to continue with gradual improvement through CY22. ” and continued efforts on profitability. Global retail demand remains strong with record orders and low inventories. A favorable mix, a recovery in sales and cost reduction initiatives should support margins at future while focusing on debt reduction (target of near debt freedom by FY24) will contribute to balance sheet strength.In addition, Tata Motors’ electric vehicle portfolio leads the space Electric Vehicle National and, by securing strategic investors, it is well placed to build on its initial success Maintain purchase with the March 23 SOTP of INR 550 standalone/JLR valued at 10x/2.5x EV/EBIDTA ).isks.”

Meanwhile, Kotak Institutional Equities analysts Rishi Vora and Eswar Bavineni said, “We have refined our consolidated EBITDA estimates for fiscal year 2023-25E. Although the short term may remain volatile for JLR due to risk recession in the EU, we believe the company has done well to improve the structural profitability of the business over the past few years With the chip situation improving, we believe JLR is well positioned to benefit given its successful new launches and strong order book.Additionally, we believe the domestic CV cycle recovery will continue as the freight rate continues to firm and fleet utilization levels The company’s successful new launches in the domestic ICE PV segment as well as growing consumer demand for electric vehicles remain a positive. BUY on stock with a revised FV of Rs500 (from Rs470 earlier) as we move to September 2024E (from June 2024E earlier).”

CRISIS :

On BSE, the Crisil share is at ₹3,261.60 each. The company has a market capitalization of ₹23,824.25 crore.

Shares of Crisil have jumped more than 27% in one year. Stocks were around ₹2,566 each last year on August 12.

CRISIL is a leading, agile and innovative global analytics company driven by its mission to make markets work better. It is India’s leading provider of ratings, data, research, analytics and solutions. The company has provided independent opinions, actionable insights, and effective solutions to more than 100,000 customers.

Disclaimer: The opinions and recommendations made above are those of individual analysts or brokerage firms, and not of Mint.

First post